A Clinical Study of FT1 in Patients With Short Bowel Syndrome
Chongqing Peg-Bio Biopharm Co., Ltd. · Short Bowel Syndrome · SBS
Phase 2
Recruiting
8
2026-07
Industry sponsor intelligence
Chongqing Peg-Bio Biopharm Co., Ltd.Clinical Pipeline.
Lead-sponsor view of Chongqing Peg-Bio Biopharm Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 8
Pipeline overview
Programs by phase and activity.
Velocity
Chongqing Peg-Bio Biopharm Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Glucagon → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Chongqing Peg-Bio Biopharm Co., Ltd. studies.
This page groups studies where Chongqing Peg-Bio Biopharm Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates